<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="768">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00168233</nctid>
  <trial_identification>
    <studytitle>Impact of HIV and Its Treatment on Reverse Cholesterol Transport</studytitle>
    <scientifictitle>Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>54/05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 - No antiretroviral therapy for 12 months

2 - Initiating ARV therapy with an NNRTI based regimen

3 - Initiating ARV therapy with a PI based regimen

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Male patients with HIV infection (3 groups of 50 patients each)

          -  HIV infected patients, na誰ve to ARV therapy and not likely to need to commence therapy
             for the duration of follow-up (12 months)

          -  HIV-infected patients, PI na誰ve, initiating therapy with PI-containing HAART (ARV
             na誰ve or NNRTI experienced changing to PI regimen)

          -  HIV-infected patients na誰ve to ARV therapy, initiating NNRTI-containing regimen</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria

          -  Treatment with any form of lipid lowering drugs, including fish oils.

          -  Body Mass Index greater than 27.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>44</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital and Baker Heart Research Institute - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Alfred</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate the effect of treatment of HIV infection with highly active antiretroviral
      therapy on individual steps of reverse cholesterol transport, endothelial function and
      intima-media thickness in HIV patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00168233</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dmitri Sviridov, Dr</name>
      <address>Baker Heart Research Institute, Commercial Road, Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>